| Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity P Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang, M Cantarini, K Pickup, ... Clinical Cancer Research 22 (20), 5130-5140, 2016 | 791 | 2016 |
| Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background BR Davies, H Greenwood, P Dudley, C Crafter, DH Yu, J Zhang, J Li, ... Molecular cancer therapeutics 11 (4), 873-887, 2012 | 537 | 2012 |
| Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent KM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ... Journal of medicinal chemistry 61 (22), 9889-9907, 2018 | 330 | 2018 |
| PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based … P Poulin, RDO Jones, HM Jones, CR Gibson, M Rowland, JY Chien, ... Journal of pharmaceutical sciences 100 (10), 4127-4157, 2011 | 231 | 2011 |
| Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs N Colclough, K Chen, P Johnström, N Strittmatter, Y Yan, GL Wrigley, ... Clinical Cancer Research 27 (1), 189-201, 2021 | 226 | 2021 |
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance BJ Ring, JY Chien, KK Adkison, HM Jones, M Rowland, R Do Jones, ... Journal of pharmaceutical sciences 100 (10), 4090-4110, 2011 | 219 | 2011 |
| Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper G Illuzzi, AD Staniszewska, SJ Gill, A Pike, L McWilliams, SE Critchlow, ... Clinical Cancer Research 28 (21), 4724-4736, 2022 | 173 | 2022 |
| A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 164 | 2018 |
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution R Do Jones, HM Jones, M Rowland, CR Gibson, JWT Yates, JY Chien, ... Journal of pharmaceutical sciences 100 (10), 4074-4089, 2011 | 156 | 2011 |
| Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis MJ Ahn, CH Chiu, Y Cheng, JY Han, SB Goldberg, A Greystoke, ... Journal of Thoracic Oncology 15 (4), 637-648, 2020 | 154 | 2020 |
| AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules SM Guichard, J Curwen, T Bihani, CM D'Cruz, JWT Yates, M Grondine, ... Molecular cancer therapeutics 14 (11), 2508-2518, 2015 | 151 | 2015 |
| The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression Y Wallez, CR Dunlop, TI Johnson, SB Koh, C Fornari, JWT Yates, ... Molecular cancer therapeutics 17 (8), 1670-1682, 2018 | 124 | 2018 |
| Free Drug Theory–No Longer Just a Hypothesis? SG Summerfield, JWT Yates, DA Fairman Pharmaceutical Research 39 (2), 213-222, 2022 | 96 | 2022 |
| Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014) FT Musuamba, E Manolis, N Holford, SYA Cheung, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 6 (7), 418-429, 2017 | 88 | 2017 |
| Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738 S Checkley, L MacCallum, J Yates, P Jasper, H Luo, J Tolsma, ... Scientific reports 5 (1), 13545, 2015 | 80 | 2015 |
| Structural identifiability of physiologically based pharmacokinetic models JWT Yates Journal of pharmacokinetics and pharmacodynamics 33 (4), 421-439, 2006 | 78 | 2006 |
| Assessment of gadoxetate DCE‐MRI as a biomarker of hepatobiliary transporter inhibition JL Ulloa, S Stahl, J Yates, N Woodhouse, JG Kenna, HB Jones, ... NMR in biomedicine 26 (10), 1258-1270, 2013 | 75 | 2013 |
| Comparison of in‐vivo and in‐silico methods used for prediction of tissue: plasma partition coefficients in rat H Graham, M Walker, O Jones, J Yates, A Galetin, L Aarons Journal of Pharmacy and Pharmacology 64 (3), 383-396, 2012 | 73 | 2012 |
| Model-based drug discovery: implementation and impact SAG Visser, M Aurell, RDO Jones, VJA Schuck, AC Egnell, SA Peters, ... Drug discovery today 18 (15-16), 764-775, 2013 | 68 | 2013 |
| PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets P Poulin, HM Jones, R Do Jones, JWT Yates, CR Gibson, JY Chien, ... Journal of pharmaceutical sciences 100 (10), 4050-4073, 2011 | 68 | 2011 |
